Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

Now Viewing

EP: 1.Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

EP: 2.Biochemical and Clinical Progression: The Two Faces of Relapsed MM

EP: 3.Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

EP: 4.Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

EP: 5.REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

EP: 6.Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

EP: 7.Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

EP: 8.Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

EP: 9.CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

EP: 10.Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

Transcript:

udy Schreiber, PhD, RN: Hi, good morning and welcome to Cancer Network’s Face-Off. Today we’re going to focus on multiple myeloma and chronic myeloid leukemia [CML]. My name is Judy Schreiber, and I’m the program host today. So, a little bit about the program. Face-Off is a series that’s a little different than many of the educational programs that you’re used to.… Make no mistake, it’s educational at its core, but it’s also designed to be fun. What makes Face-Off different from other educational events is the fact that it’s not just a presentation, but it’s more than that. It’s a competition. Here in Pasadena, we have the visiting team online from the University of Washington Fred Hutchinson Cancer Center captained by Dr Vivian Oehler and the home team from City of Hope captained by Dr Paul Koller. They’re not just presenting data to you, but they’re presenting [data to] each other.

The visiting team will lead off. Visiting teams always go first, and they will be presenting several studies to the home team, after which the home team will have the opportunity to challenge the visiting team. Presenters should make sure that their presentation contains certain levels of enthusiasm. At the end of each Q&A session they’ll appear on your screen for the fans. That’s you in the audience. If you have any questions…or comments you want to make, you’re free to also make those comments. We have a number of attendees here in Pasadena. Then…at the end of the multiple myeloma section, then also at the end of the CML section, we’re going to have a couple of questions. [We’ll use] the answers to the questions…to score how each team did. The team with the most correct answers will go home the winners. Trophies, ribbons, and bragging rights forever. Not only that, but Cancer Network is donating a starting amount of $2000 to your institution’s fellows’ travel fund for participating in this program. For the team that wins, they get an additional $1000 for their fellows’ travel fund. So, cheer your colleagues on. At this time, I would like Dr Oehler first to introduce herself and her team. When she’s done, we’ll follow up with Dr Kohler introducing his team here.

Vivian G. Oehler, MD: Good morning, everyone. Dr Cowan here I thought was our fearless leader. But Dr Andrew Cowan is going to be our myeloma person. Dr Rahul Banerjee is also with us today. I’m Vivian Oehler, and we’re all from the Fred Hutch[inson Cancer Center]. Good morning, everyone. I’m going to say you all look very serious.

Judy Schreiber, PhD, RN: Is that better?

Paul B. Koller, MD: My turn. My name is Paul Koller. I’m from City of Hope. I will be talking about CML. Then we have Dr Lawrence Liu, who’s one of our fellows at City of Hope who will be giving us some information on myeloma. Dr Murali Janakiram, who will also be talking about myeloma. We’re excited to participate in this. I think the seriousness was because I was not expecting to talk at all right now.

Murali Janakiram, MD, MS: We just thought it was a win and we can go home.

Transcript is AI-generated and edited for clarity and readability.